Catalent, Inc. (CTLT)
Stock Price Chart
Key Info
| Market Cap | 14.57B |
| Revenue (ttm) | 2.87B |
| Net Income (ttm) | 137.60M |
| Shares Out | 163.81M |
| EPS (ttm) | 0.69 |
| PE Ratio | 128.80 |
| Forward PE | 40.65 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 5, 2020 |
| Last Price | $88.87 |
| Previous Close | $88.18 |
| Change ($) | 0.69 |
| Change (%) | 0.78% |
| Day's Open | 88.59 |
| Day's Range | 87.55 - 89.14 |
| Day's Volume | 152,740 |
| 52-Week Range | 31.04 - 91.18 |
More Stats
| Market Cap | 14.57B |
| Enterprise Value | 17.16B |
| Earnings Date (est) | Aug 31, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 163.81M |
| Float | 154.05M |
| EPS (basic) | 0.72 |
| EPS (diluted) | 0.69 |
| FCF / Share | -0.25 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | 0.78% |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 2.74M |
| Short Ratio | 1.83 |
| Short % of Float | 2.20% |
| Beta | 1.63 |
| PE Ratio | 128.80 |
| Forward PE | 40.65 |
| P/FCF Ratio | n/a |
| PS Ratio | 5.07 |
| PB Ratio | 6.54 |
| Revenue | 2.87B |
| Operating Income | 333.70M |
| Net Income | 137.60M |
| Free Cash Flow | -36.70M |
| Net Cash | -2.59B |
| Net Cash / Share | -15.80 |
| Gross Margin | 28.03% |
| Operating Margin | 11.62% |
| Profit Margin | 3.80% |
| FCF Margin | -1.28% |
| ROA | 3.95% |
| ROE | 6.23% |
| ROIC | 5.80% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,518 | 2,463 | 2,075 | 1,848 | 1,831 | 1,828 | 1,800 | 1,695 | 1,532 |
| Revenue Growth | 2.22% | 18.7% | 12.3% | 0.94% | 0.17% | 1.52% | 6.22% | 10.64% | - |
| Gross Profit | 805 | 753 | 655 | 588 | 615 | 599 | 569 | 559 | 502 |
| Operating Income | 274 | 269 | 234 | 218 | 260 | 241 | 204 | 198 | 186 |
| Net Income | 137 | 83.60 | 110 | 112 | 212 | 16.20 | -49.60 | -24.40 | -54.00 |
| Shares Outstanding | 146 | 133 | 125 | 125 | 124 | 117 | 117 | - | - |
| Earnings Per Share | 0.90 | 0.63 | 0.87 | 0.89 | 1.75 | 0.21 | -0.66 | -0.32 | -0.72 |
| EPS Growth | 42.86% | -27.59% | -2.25% | -49.14% | 733.33% | - | - | - | - |
| Operating Cash Flow | 248 | 375 | 300 | 155 | 172 | 178 | 138 | 87.90 | 99.70 |
| Capital Expenditures | -218 | -175 | -139 | -138 | -141 | -122 | -120 | -102 | -83.30 |
| Free Cash Flow | 30.10 | 200 | 160 | 17.60 | 30.80 | 56.80 | 18.10 | -14.10 | 16.40 |
| Cash & Equivalents | 345 | 410 | 288 | 132 | 151 | 74.40 | 106 | 139 | 0.00 |
| Total Debt | 2,959 | 2,721 | 2,080 | 1,861 | 1,881 | 2,711 | 2,692 | 2,684 | - |
| Net Cash / Debt | -2,614 | -2,311 | -1,791 | -1,729 | -1,730 | -2,636 | -2,585 | -2,545 | 0.00 |
| Assets | 6,184 | 4,531 | 3,454 | 3,091 | 3,138 | 3,090 | 2,950 | 3,139 | - |
| Liabilities | 3,896 | 3,444 | 2,731 | 2,455 | 2,504 | 3,462 | 3,360 | 3,490 | - |
| Book Value | 1,682 | 1,087 | 724 | 636 | 634 | -371 | -411 | -351 | - |
Company Profile
Company Details
| Full Name | Catalent, Inc. |
| Country | United States |
| Employees | 12,300 |
| CEO | John R. Chiminski |
Stock Information
| Ticker Symbol | CTLT |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic |
| Unique Identifier | NYSE: CTLT |
| IPO Date | July 31, 2014 |
Description
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics and Specialty Drug Delivery segment engages in the drug substance development and manufacturing; drug product clinical and commercial manufacturing; and integrated clinical and commercial supply solutions for protein and gene therapy biologics and specialty small molecules through injection, inhalation, and ophthalmic routes. The Oral Drug Delivery segment formulates, develops, and manufactures technologies and related integrated solutions for a range of oral dose forms, including its proprietary fast-dissolve Zydis tablets and conventional tablets, capsules, and sachet products. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain clinical supply services. The company serves pharmaceutical, biotechnology, consumer health, animal health, medical devices, and cosmetics industries. It has an agreement with Cycle Pharmaceuticals Ltd. to develop formulations targeting rare disease patients; a collaboration with the Janssen Pharmaceutical Companies, as well as Ennaid Therapeutics; a partnership with Arcturus Therapeutics Holdings Inc. to support the manufacture of LUNAR-COV19; and has collaboration with Moderna, Inc. for manufacturing mRNA-based COVID-19 vaccine candidate. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.